Press Releases Inhibrx, Inc.

Equities

INBX

US45720L1070

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-24 pm EDT			5-day change	1st Jan Change
34.14 ^USD	-0.15%		-1.61%	-10.16%

May. 24	Inhibrx Shareholders Approve Sale of INBRX-101 Assets to Sanofi	MT
May. 09	Inhibrx, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Inhibrx Inc. Stockholders Approve Sale of INBRX-101 to Sanofi	May. 24	PR
Inhibrx, Inc. Announces Updated When-Issued Trading Date for Anticipated Spin-Off	May. 10	PR
Inhibrx : Reports First Quarter 2024 Financial Results and Recent Corporate Highlights - Form 8-K	May. 09	PU
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	May. 09	BU
Inhibrx, Inc. Announces Record Date and Expected Distribution Time for Anticipated Spin-Off and the Expected Merger Effective Time for Anticipated Merger	May. 08	PR
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - HMST, FREE, EVBG, INBX	Mar. 26	PR
Inhibrx Reports Fourth Quarter and Fiscal Year 2023 Financial Results	Feb. 28	PR
INHIBRX INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inhibrx, Inc. - INBX	Feb. 10	BU
Sanofi bets $1.7b on potential best-in-class rare disease therapy	Jan. 24	AQ
Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline	Jan. 24	AQ
Unitholder Alert: Ademi LLP investigates whether Inhibrx, Inc. has obtained a Fair Price in its transaction with Sanofi	Jan. 23	PR
INBX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Inhibrx, Inc. Is Fair to Shareholders	Jan. 23	BU
Mintz Launches Podcast Series On Women Leaders In Health Care	Dec. 13	AQ
Inhibrx Announces Preliminary Data from the Phase 1 Trial of INBRX-109 for the Treatment of Ewing Sarcoma	Nov. 02	PR
Inhibrx Announces Participation in Upcoming Scientific Conferences	23-10-18	PR
Inhibrx : Poster Presentation	23-10-16	PU
Inhibrx Retains Rights to INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency Outside of the United States and Canada	23-09-20	AQ
Inhibrx Announces $200 Million Private Placement Financing	23-08-29	PR
Inhibrx Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights	23-08-07	PR
Inhibrx Granted Fast Track Designation for INBRX-101 for the Treatment of Alpha-1 Antitrypsin Deficiency	23-05-30	PR

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Inhibrx, Inc.

Equities

INBX

US45720L1070

Press Releases

Filters